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Fifteen normal male volunters received 400, 800, and 1200 mg doses of  ibuprofen as 1, 2, or 3 
tablets, respectively, in crossover fashion, then 420 mg in solution form during the fourth week. 
Plasma concentration of  ibuprofen was measured by an HPLC method. Individual subject con- 
centration-time (C,t) data following the solution were analyzed by two different methods, and 
results unequivocally indicated the open two compartment model with first order absorption. 
However, the computer fitting of  both arithmetic and geometric mean concentrations led to a 
different model. A method was developed to obtain absorption data (fraction of  drug absorbed, 
F~, versus time)for a multicompartmental system from oral data alone, without intravenous data. 
The method assumes that Vp is constant intrasubject and that absorption is complete following 
administration o f  both the solution and tablets. The method was successfully applied to the ibuprofen 
tablet data. It was shown also that such a method is necessary to obtain ibuprofen absorption 
data since intrasubject variation of  the microscopic rate constants k j2, k21, and kel (as reflected 
by the intrasubject variation o f  the hybrid rate parameters h I and A2 or fl and ce) is o f  the same 
order of  magnitude as intersubject variation. Absorption of  ibuprofen from tablets was shown not 
to be simple first order as for the solution. The absorption profiles following one tablet were 
S-shaped, while those following 2 or 3 tablets had partial linear segments indicating zero order 
absorption. 
KEY WORDS: ibuprofen; absorption; disposition; multicompartmental model; solution; 
tablets; absorption in multicompartment system without intravenous data. 
I N T R O D U C T I O N  
Ibupro fen ,  [2- (4- isobutylphenyl) ]propionic  acid, is an orally 
adminis te red ,  nons te ro ida l  an t i inf lammatory  agent  which is used extensively 
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in the treatment of arthritis. Its biological properties (1, 2), metabolism (3), 
and binding to albumin (4, 5) have been described. Two GLC assay methods 
(6, 7) and several HPLC assay methods (8-14) have been reported. We have 
described an HPLC assay for ibuprofen and its major metabolites in biologi- 
cal fluids (15). Whitlam et al. (16) described the transsynovial distribution 
of ibuprofen in arthritic patients. Steady et al. (17) reported on the bioavaila- 
bility of the drug in man following administration as tablets. In the first 
article in this series (18), we described a 15 subject study in young adults 
in which the subjects received 400, 800, and 1200 mg doses of ibuprofen as 
1, 2, and 3 tablets, respectively, in crossover fashion one week apart; then 
on the fourth week all subjects received a dose of 420 mg of the drug in 
the form of an aqueous solution. Two other articles in this series have been 
published (19, 20). 
Kearns and Wilson (14) administered 400mg of sodium ibuprofen 
intravenously over a 5 min period to a dog. They fitted the post infusion 
data to a biexponential equation and modeled disposition of the drug using 
an open two compartment model. Unfortunately, to date there is no 
intravenous dosage form of ibuprofen available for use in man. In this 
article we infer the disposition model of ibuprofen in man from total plasma 
concentrations following administration of a 420 mg dose in the form of 
the aqueous solution. In addition, a new absorption equation (21), appli- 
cable to the open two compartment model, was applied to total plasma 
concentrations following administration of the different doses in tablet form 
to the young adults to produce absorption plots for ibuprofen in man. 
EXPERIMENTAL PROCEDURE 
Studies in Man 
Fifteen Caucasian male subjects with mean age 25 (range 22-35) years 
and mean body weight 78 (range 70-92.5) kg were selected from respondents 
to an advertisement based on subject availability, reliability, medical history, 
physical examination, and results of blood and urinary analyses. In crossover 
fashion they were dosed with 1, 2, or 3 commercial 400 mg ibuprofen tablets 
(Motrin; Upjohn) with treatments one week apart. In the fourth week, all 
subjects received a 420 mg dose in the form of an aqueous solution of 
ibuprofen. Following tablet treatments blood was collected at 0, 0.167, 0.333, 
0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 hr, and following solution treatment, 
blood was collected at 0, 0.0833, 0.167, 0.25, 0.333, 0.5, 1, 1.5, 2, 3, 4, 6, 
and 8 hr. The sampling schemes for tablets and solution were different 
because the drug was absorbed appreciably faster following administration 
of the solution than following the tablets. Blood was converted to plasma 
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immediately after collection, frozen, and stored in the freezer at -10~ until 
just prior to assay. Plasma was assayed for total ibuprofen by the HPLC 
assay described formerly (15). 
Data  Analysis  
Individual subject sets of concentration-time (C,t) data were fitted to 
a triexponential equation using the method of least squares in a program 
written by Dr. Jeffrey Fox and an Apple II microcomputer. Initial estimates 
were obtained with Dr. Fox's program, called RSa-RIP, also using the micro- 
computer. Both arithmetic and geometric mean plasma concentrations of 
the 15 subjects following the solution were fitted by the same procedure 
using equal, 1/Y and 1/Y 2 weights for different fits to provide six different 
triexponential equations. 
For those data sets which gave a triexponential equation such that the 
negative coefficient, - (BI + B2), was associated with the largest exponent,  
ka, the absorption rate constant, then the model of Scheme I was assumed, 
and the parameters k~2, k21, kez, and Vp were estimated from the three 
coefficients, three exponents, and the dose using the equations of  Wagner 
(22). The new "Exact Loo-Riegelman" equation of Wagner (21) is given 
as Eq. (1) and applies if the disposition model is as shown in Scheme II. Here 
A t =  Cr +kel Cdt +kin e -k2'r e +k2~t. C. dt (1) 
Vp 
where Ar  is the amount of drug absorbed to time T; Vp is the volume of 
the central compartment; Cr  is the concentration of drug in the central 
T " r compartment at time T; Io Cdt is the area under the C,t curve to time ; 
fro e+k2~t" C. dt is the area under the curve of e+k2'tC, t; and the rate 
constants are those of Schemes I and II. In addition, the total amount  of  
k i k12 
Scheme I. Scheme II. 
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drug absorbed, Aoo, divided by Vp, is given by 
A~ = kel C dt (2) 
Vp 
and the fraction of drug absorbed, Fa, is given by 
Fa = AT/Vp =--AT (3) 
A ~ / V  v A~ 
Initially, in evaluating C,t data following tablets, Eqs. (1) and (2) were 
applied using the k12, k21, and kel values derived from solution data via the 
triexponentail fitting. However, in almost all cases the AT/Vp values 
increased with time then decreased, or the values kept increasing throughout 
most of the time sampling. It was found that these trends were indicative 
that the wrong rate constants were being employed in Eq. (1), and they 
were "wrong" as a result of intrasubject variation, particularly in k12 and 
k21. Hence, a new procedure was evolved to derive the constants from 
terminal C,t data of the same data set to which Eq. (1) was applied to the 
initial C,t data. 
The new procedure involved the assumption that Vp is constant 
intrasubject for solution and tablet treatments and that absorption following 
both solution and tablet treatments is complete. Bioavailability of ibuprofen 
from tablets relative to the solution was discussed in a previous article (18). 
The procedure is as follows. Vp is estimated from solution data using 
Ds 
Vv - k ; t (AUC 0-co)s (4) 
Here D~ is the dose of ibuprofen (420 mg) administered in solution form, 
kit is the first order model elimination rate constant (Scheme I) estimated 
from the triexponential fit of the solution C,t data, and ( A U C  0-oo)s is the 
total area under the C,t curve following the solution. 
Terminal C,t data from 3 to 12 hr following a tablet treatment were 
fitted to the biexponential equation (Eq. 5) by the same procedure as 
described above to obtain the triexponential fits of solution data for 0-8 hr 
(Eq. 6) where to is the lag time: 
C = BI e -A'' +B2 e -AJ (5) 
C = BI e -A'~' 'o) +B2 e-A2c'-'~ (BI +B2) e -k~176 (6) 
It should be noted that pharmacokinetic theory indicates that the magnitudes 
of B~ and B2 in Eqs. (5) and (6) are different. However, A1 and ~2 would 
be the same if there was no intrasubject variation, but of different magnitudes 
if there was intrasubject variation in the parameters k l2  , k21 , and ke~. The 
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model rate constants were estimated from tablet data using Eqs. (7)-(9). 
In these equations, 
D, 
k'el - (7) 
V;(AUC 0-oo), 
k~l = ~1~2 (8) 
ktet 
kt,2 = , A1 -l-~-2- k e l -  k2, (9) 
Dt is the dose if ibuprofen is administered as tablets, Vp is from Eq. (4), 
(AUC 0-~)t  is the total area under the C,t curve following the tablet 
treatment and A1 and A2 are from Eq. (5). The values of kt12, k~l, ktel obtained 
from Eqs. (7)-(9) were then substituted into Eq. (1), and Eq. (1) was applied 
to the C,t data in the 0-3 hr time range of the same data set which gave 
Eq. (5) in the 3-12 hr range. 
In some cases (see note a of Table liD, terminal tablet C,t data were 
fitted very well with only a monoexponential rather than a biexponential 
equation. In these cases, the Wagner-Nelson method (24) was applied rather 
than the method described herein using Eqs. (1)-(5) and (7)-(9). In some 
cases Eqs. (5) and (7)-(9) led to negative values of Ul2. Attempts were then 
made to calculate a different kte~ value using Eq. 10 from Dittert et al. (23), 
(k~2 + k~,)A, - (A,) 2 
ktel = (10) 
k~l --Al 
where A~ is from the mono- or biexponential fit of terminal tablet C,t data. 
When solution C,I data were computer-fitted with the triexponential Eq. 
(6), an estimate of k~, the absorption rate constant, was obtained. Hence, 
the fraction absorbed, F~, following administration of the solution, could 
be described by Eq. (11). Values of F~ obtained with 
F~ = 1 - e  -k,,(t-t~ (11) 
were compared with values of F,  obtained from applications of Eqs. (1)-(3). 
In the computer fitting of C,t data, three measures of fit were employed. 
These were as follows. The coefficient of determination, r 2, was obtained 
from Eqs. (12)-(14), where 
r2= l  ~ d2 
S~ (12) 
2 C 2 __ (~" C)2 S~=Y~ 
N 
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S 2 is the corrected sum of squares of the observed concentrations, C, and kc 
C is the model-predicted concentrations (from either Eq. 5 or 6). Corr. is 
the correlation coefficient for the linear regression of C on C. The standard 
deviation, S, was estimated with 
S=~/~  d 2 / ( N - P )  (15) 
where N is the number of data points fitted, and P is the number of 
parameters estimated, namely, 4 for Eq. (5) and 6 for Eq. (6). The weighting 
scheme which gave the smallest Y, d 2, and hence the smallest value of  S 
(Eq. 15), and largest value of r 2 (Eq. 12) was chosen (Tables I and II). 
RESULTS 
Table I lists results of fitting solution C,t data of 13 individual subjects 
to the triexponential Eq. (6). The type of weighting, namely equal, 1 / Y  and 
1/y2,  which gave the best fit is indicated in the second column of  Table I. 
The estimated parameters A1, A2, ka, and to (but not B1 and B2) are listed 
as well as the measures of  fit obtained with Eqs. (12)-(15). In the last four 
columns are listed the derived parameters Vp, k~2, k~,  and kSt; note that 
A~ < k21 < A2 < ka. These fittings indicate that the model of  Scheme I is the 
appropriate model and the model of Scheme II is the disposition model. 
The solution data of subject ~ 3 gave a triexponential equation of the type 
of Eq. (16) where the negative coefficient, -B2, is associated with the 
intermediate size rate constant, A2, which implies a different model: 
C = B 1 e -x~(t-t~ - B 2 e -A2(t-t~ +B 3 e -x3(t-t~ (16) 
Both the arithmetic and geometric mean plasma concentrations of  15 sub- 
jects following the solution, each with equal, 1 /Y  or 1 / y 2  weighting, gave 
equations like Eq. 16, as indicated in Table II. Such an equation is appropri-  
ate for the model shown in Scheme III, where A1 = k30, A2 = k12, /~3 = k23, 
and k30 < k~2 < k23. The corresponding disposition model would be the one 
compartment open model shown in Scheme IV. The solution data of  subject 
4~ 15 gave a triexponential equation of the type 
= BL e -A~t -B2  e-'~2t-B3 e -~3t (17) 
which indicates the model shown in Scheme I, but where At < k~ < k21 < A2. 
Thus, 14 out of 15 or 93% of the individual subject solution C,t data 
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indicated that the appropriate model is the open two compartment model 
of Schemes I and II, but the mean data did not reflect the same model 
(Table II). 
Figure 1 shows a typical triexponential fit of solution C,t data (for 
subject # 2). The fitting of typical terminal tablet C,t data to a biexponential 
equation is also shown in the lower panel of Fig. 1. Figure 2 is a plot of 
Fa values for the solution estimated with Eq. (I)-(3) using the k~2, k~l, and 
kit values listed in Table I vs. Fa values obtained with Eq. (11) using the 
ko and to values from the triexponential fittings listed in Table I. Figure 2 
is based on the pooled data of the 13 subjects whose triexponential equation 
had the form of Eq. (6). This is evidence that Eqs. (1)-(3) provide accurate 
values of fraction of ibuprofen absorbed. The least squares line had a slope 
of 1.045, which did not differ significantly from unity, and an intercept of 
-0.0059, which did not differ significantly from zero, with r = 0.980. In Fig. 
2, the line of identity with a slope equal to unity is drawn. Figure 3 is a 
plot of Fa versus time for the solution of ibuprofen showing data for subject 
# 9, who absorbed drug from the solution the most rapidly, and that for 
subject # 7, who absorbed the drug from solution the slowest. The points 
in the plots were obtained with Eqs. (1)-(3) while the solid lines drawn 
through the points were estimated with Eq. (16). Thus, this is additional 
evidence that Eqs. (1)-(3) provide accurate estimates of Fa. 
Terminal C,t data following the ibuprofen solution were also fitted to 
biexponential equations (Eq. 5), and Eqs. (7)-(9) were then applied to 
generate k~2, k~l, and k~l values (rather than the kt12, k~l, and ktet as in Eqs. 
7-9). These were different values than those listed in Table I. The two sets 
of microscopic rate constants for the solution were then used, separately, 
in Eqs. (1)-(3) to generate two sets of FaT values. In Fig. 4, Fa from the 
biexponential fit is plotted vs. Fa from the triexponential fit. The least 
squares line had a slope of 1.096, which was not significantly different from 
unity, and an intercept of -0.039, which was not significantly different from 
zero, with r = 0.972. The line drawn through the points is the line of identity 
with slope equal to unity. This figure provides support for the fitting of 
terminal C,t data to biexponential equations in order to estimate the h~ 
and A2 values from which k~2 and k2~ values could be estimated. Table III 
lists the estimated parameters and measures of fit of terminal tablet C,t 
data to monoexponential or biexponential equations. These were excellent 
fits. 
The apparent elimination rate constants (A0 obtained in the mono- 
exponential or biexponential fittings (for treatments with 1, 2, or 3 tablets) 
and triexponential fittings (solution data) are listed in Tables I and III. 
Typical absorption plots following tablet treatments A, B, and C are shown 
in Figs. 5, 6, and 7, respectively. Although absorption of ibuprofen from 
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Fig. 1. Upper  panel: typical triexponential fit (to Eq. 6) of solution C,t data of 
subject 4~ 2 (see Table 1 for estimated parameters and measures of fit). Lower 
panel: typical biexponential fit of terminal C,t tablet data. 




























R I I I I I 
0.2 0.4 0.6 0.8 1.0 1.2 
1 - e - k a ( t - t o  ) WHERE k a AND t o  FROM THE TRIEXPONENTIAL FIT 
Fig. 2. A plot of/7o values obtained with Eqs. (1)- (3)  using the k~2 , k~i , and  k~l values listed 
in Table I vs. the corresponding F~ values estimated with Eq. (16) using the k s and t o values 
from the triexponential fittings of solution data (see Table I). This  is excellent evidence to 
support the new absorption equation (Eq. 1). The least squares line for the data is Y = -  
1 . 0 4 5 X - 0 . 0 0 5 9  wi th  r = 0.980. Line is identity with slope equal to unity (see text).  
solution obeys first order kinetics (Fig. 3), absorption of the drug following 
tablets is not simple first order. Following one 400 mg tablet, the absorption 
plots are S-shaped (Fig. 5) as Digenis (25) reported using scintography. 
Following the 800 mg two tablet dose, there begins to be evidence of some 
zero order absorption (Fig. 6). Following the 1200 mg three tablet dose, the 
evidence for zero order absorption becomes more pronounced (Fig. 7). 
In the first article (18) it was reported that ibuprofen exhibits nonlinear 
plasma protein binding and that a plot of the area under the total (bound + 
free) plasma concentration-time curve was a nonlinear function of the mg/kg 
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Fig. 3. Absorption plots for ibuprofen from solution showing the range of values. Open 
circles are for subject # 9, who absorbed the drug most rapidly. Closed circles are for 
subject # 7, who absorbed the drug the slowest of the panel. The points are derived 
from Eqs. (1)-(3). The lines are based on Eq. (16). This, again, provides excellent 
experimental evidence of validity of Eqs. (1)-(3). 
dose of the drug; however, a plot of the area under the free (unbound) 
plasma concentration-time curve was essentially linear. Linearity of such 
plots implies constant plasma clearance. Although the average bound/free 
ratio of ibuprofen in the study under discussion (18) was 180, almost all 
the observed binding values were in the lower one-third of the overall 
binding curves. Hence, although the data were nonlinear, they were 
minimally so. Although we believe that input kinetics should be determined 
from total plasma concentrations of drug even in cases of such nonlinearity, 
one may ask what would happen if free concentrations were similarly 
analyzed. We have done so with the free ibuprofen plasma concentrations 
using the same methods as used for total concentrations. Free plasma 
concentrations following the solution of ibuprofen were computer-fitted to 
Eq. (6); rate constants, ka, could be compared in 13 of the 15 subjects. The 
mean kt~ from total concentrations, 6.76 hr -1, did not differ significantly 
from the mean k~ from free concentrations, 6.07hr -1 (paired t=  1.89, 
O.lO>p > 0.05); least squares linear regression of Y= k] from free vs. 
P h a r m a c o k i n e t i c s  o f  Ibuprofen  in M a n  IV  3 9 3  
f 
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FRACTION ABSORBED USING k i j 's  FROM TRIEXPONENTIAL FIT 
Fig.  4. A plot of F a derived from terminal biexponential fits of solution data vs F, z derived 
from triexponential fittings of solution data. This provides justification for fitting terminal 
C,t data following tablets to a biexponential equation to estimate U~z , kit , and k~l. The 
least squares line is Y= 1.096X-0.039 with r= 0.970. Line is identity with slope equal to 
unity (see text). 
X = k ' ~  from total gave a slope o f  0.934 with r = 0 . 9 6 6  ( p < 0 . 0 0 1 ) ;  the 
or thogonal  least squares line had a slope of  0.965. For  the highest dose 
(1200mg as 3 tablets), fraction absorbed values derived f rom total con- 
centrations, F~, were compared  with fraction absorbed values derived f rom 
free concentrat ions,  F~. A compar ison was possible using the poo led  data 
o f  6 subjects with 31 pairs o f  Fa values. The mean  F~ value o f  0.513 did 
not differ significantly f rom the mean F~ value o f  0.533 (paired t = 1.62, 
p >  0.10). The correlat ion o f  Y =  FY, vs. X = F'a gave a slope o f  1.03, which 
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Fig. 5. Typical plots of F a vs time following treatment A (one tablet). Numbers refer to 
subjects. 
was not significantly different from zero, with r=0.973 (p <0.001). Thus, 
results obtained by analyzing free concentrations were essentially the same 
as those obtained by analyzing total concentrations. In addition, intrasubject 
variation of pharmacokinetic parameters derived from free concentrations 
were of  the same magnitude as those derived from total concentrations. 
DISCUSSION 
Although first order absorption is often assumed in pharmacokinetics, 
there are few examples in the literature where there is convincing evidence 
of this. We have shown that ibuprofen administered orally in the form of 
an aqueous solution was absorbed according to first order kinetics in 14 of 
15 subjects. This was shown in two different ways: (a) by computer fitting 
C , t  data following the solution to a triexponential equation, which was 
based upon first order absorption; and (b) by applying a new absorption 
equation (21) using the microscopic rate constants k~2, k~l, and k~, which 
were derived from the triexponential fit. 
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. B  
6 
2 
1 3  
0 1 2 3 
TIME (HOURS) 
Fig. 6. Typical plots of F,, vs time following treatment B (two tablets). Numbers refer to 
subjects. 
A new method has been described to obtain absorption plots for a 
multicompartmental system without intravenous data. The method is based 
on estimating Vp following administration of the drug in solution form, 
fitting terminal C,t data following tablet(s) to a biexponential equation (Eq. 
5), then estimating the microscopic rate constants, k'~2, k;~, and k'e~ (using 
Eqs. 7-9), followed by application of a new absorption equation (Eq. 1). 
The method is valid if the absorption following solution and tablet forms 
to the same subject is complete in both cases. The method was successfully 
applied to ibuprofen C,t tablet data. The new method was developed since 
the usual assumption of the constancy of the distribution rate constants, 
kl2 and k2i, of the open two compartment model was found to be invalid 
in the case of ibuprofen. Although such constancy has hitherto been assumed 
in the case of application of the Loo-Reigelman method (26), the assumption 
has never been well tested. 
A most interesting result of the analyses of the ibuprofen data is that 
the pharmacokinetic model which one would elaborate from mean C,t 
ibuprofen solution data (see Scheme III) is not the same as the open two 
compartment model (see Scheme I) which is indicated by the analysis of 
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Fig. 7. Typical plots of F a v s  time following treatment C (three tablets). Numbers refer 
to subjects. Note the zero order absorption particularly of subject 1. 
14 out  o f  15 sets o f  ind iv idua l  subject  data.  Both the ar i thmet ic  and  geometr ic  
m e a n  da t a  were fitted by  a t r i exponent ia l  equa t ion  in which  the coefficient 
with a negat ive  sign was assoc ia ted  with the in te rmedia te - s ized  rate constant .  
However ,  in 14 out  o f  15 sets o f  ind iv idua l  subject  C,t  i bupro fen  so lu t ion  
da ta ,  the  coefficient with a negat ive  sign was assoc ia ted  with the  largest  
rate  constant .  The me thods  d iscussed  in this art icle have been  app l i ed  
successful ly  to results  ob ta ined  in a s imi lar  s tudy with f lurbiprofen,  and  
those  results  will be the subject  o f  a fu ture  publ ica t ion .  
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